Hospital Universitario de Cruces-ko ikertzaileekin lankidetzan egindako argitalpenak (35)

2023

  1. Descending mediastinitis that simulates a pharyngo-laryngeal neoplasm

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 42, Núm. 3, pp. 193-194

  2. Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 50, Núm. 8, pp. 2486-2500

2021

  1. Dependency of the remnant 131I-NaI biokinetics on the administered activity in patients with differentiated thyroid cancer

    Physica Medica, Vol. 88, pp. 45-52

  2. EANM dosimetry committee series on standard operational procedures: a unified methodology for 99mTc-MAA pre- and 90Y peri-therapy dosimetry in liver radioembolization with 90Y microspheres

    EJNMMI Physics, Vol. 8, Núm. 1

  3. Salvage brachytherapy for locally recurrent prostate cancer after single-fraction 19 Gy high-dose-rate brachytherapy: Toxicity, prostatespecific antigen kinetics, and cancer control

    Journal of Contemporary Brachytherapy, Vol. 13, Núm. 1, pp. 12-17

2020

  1. EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for 131I mIBG treatment of neuroendocrine tumours

    EJNMMI Physics, Vol. 7, Núm. 1

  2. Errare humanum est, sed in errare perseverare diabolicum: methodological errors in the assessment of the relationship between I-131 therapy and possible increases in the incidence of malignancies

    European Journal of Nuclear Medicine and Molecular Imaging

  3. Oligometastatic prostate adenocarcinoma. Clinical-pathologic study of a histologically under-recognized prostate cancer

    Journal of Personalized Medicine, Vol. 10, Núm. 4, pp. 1-9

2019

  1. Dosimetry-based high-activity therapy with 131I-metaiodobenzylguanidine (131I-mIBG) and topotecan for the treatment of high-risk refractory neuroblastoma

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 46, Núm. 7, pp. 1567-1575

  2. Late toxicity after single dose HDR prostate brachytherapy and EBRT for localized prostate cancer: Clinical and dosimetric predictors in a prospective cohort study

    Radiotherapy and Oncology, Vol. 135, pp. 13-18

  3. Re: Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma

    Journal of Vascular and Interventional Radiology

2018

  1. BRAF V600E mutation in papillary thyroid cancer and its effect on postoperative radioiodine (131I) therapy: Should we modify our therapeutic strategy?

    Cirugia Espanola, Vol. 96, Núm. 5, pp. 276-282

  2. Detection and quantification of 223Ra uptake in bone metastases of patients with castration resistant prostate carcinoma, with the aim of determining the absorbed dose in the metastases

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 37, Núm. 1, pp. 20-27

2017

  1. 131I activity quantification of gamma camera planar images

    Physics in Medicine and Biology, Vol. 62, Núm. 3, pp. 909-926

  2. Biopsia del ganglio centinela en el cáncer de pulmón

    Medicina Clinica, Vol. 148, Núm. 6, pp. 257-259

  3. Dosimetry-based treatment planning for molecular radiotherapy: A summary of the 2017 report from the Internal Dosimetry Task Force

    EJNMMI Physics, Vol. 4, Núm. 1

  4. Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma

    Clinical and Translational Oncology, Vol. 19, Núm. 11, pp. 1337-1349

  5. Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey

    EJNMMI Physics, Vol. 4, Núm. 1

2016

  1. A study using positron emission tomography of a case of vascular dementia due to left thalamic haematoma, an example of the diaschisis phenomenon

    Revista de Neurologia, Vol. 62, Núm. 9, pp. 408-410

  2. Biologically effective dose in fractionated molecular radiotherapy - Application to treatment of neuroblastoma with 131I-mIBG

    Physics in Medicine and Biology, Vol. 61, Núm. 6, pp. 2532-2551